Aim of the work: The aim was to study the outcome characteristics of systemic lupus erythematosus (SLE) in Egyptians according to the age at disease onset and gender. Patients and methods: We studied 239 SLE patients (185 adult and 54 Juvenile onset) with a female to male ratio of 9.39-1 and a mean age of 28.23 ± 8.91 years and disease duration of 5.45 ± 4.25 years. Full history taking, thorough clinical examination, laboratory and relevant radiological investigations were performed. Disease activity was assessed using SLEDAI and damage by SLICC. Renal biopsies were done in those with renal involvement. Results: The clinical manifestations, disease activity and damage and laboratory investigations of the SLE patients varied according to the age at disease onset and gender. The prevalence of damage
was obviously increased in juvenile patients and higher in males. Growth failure, delayed puberty and fibromyalgia were present more in Juvenile-onset patients. Adult onset SLE patients had a significantly higher secondary Sjo¨gren syndrome especially in females. In the present study, there was a 2.5% mortality and the commonly involved kidneys were an important cause of death. Conclusion: Measuring organ damage in SLE is important with special concern to juvenile-onset patients to allow for designing new treatments that improve control of disease activity and minimize the development of irreversible damage. The kidney appeared to be commonly involved, especially in males, indicating the importance of regular screening for early and appropriate management. 
Introduction
Although the highest prevalence of SLE is among women of childbearing age, juvenile-onset SLE (J-SLE) represents 10-20% of all SLE cases. Childhood-onset lupus patients display some differences in their disease profile and are associated with higher disease severity, and a more-rapid damage accrual compared with adult-onset SLE (a-SLE) [1, 2] . Appropriate management is critically dependent upon the proper assessment of disease activity and organ damage [3] .
Better disease outcome can be achieved if the disease burden is more precisely defined and the diagnosis and treatment algorithms are established [4] . In spite of the improved survival, new morbidities have emerged leading to altered outcome patterns [5] and SLE continues to cause significant morbidity juveniles. A better recognition of the age-specific manifestations and long-term complications is required to improve its outcome [6] . Although the clinical presentation and immunological findings are similar to those of adults, juvenile SLE patients usually have a more severe disease at onset with higher rates of organ damage and mortality [7, 8] . As a result of the increased life expectancy, SLE patients are faced with considerable morbidity from disease activity, side effects of medications, and co-morbid conditions [9] . Disease activity and organ damage at the baseline predict the latter. Careful monitoring of SLE disease activity is of value and individually tailored treatment is guided by the predictors of course and outcome [10] . It is recommended that SLE outcome be assessed in terms of disease activity and damage [11] .
Variations in SLE clinical manifestations, serology and outcomes have been also related to gender differences [12] . It has been suggested that childhood SLE is not rare in Egypt and Africa [13] . These associations have been retrospectively evaluated in SLE Egyptian children [14] . The juvenile onset SLE patients as well as the male SLE patients represent important subsets which are commonly overlooked and require special attention. The objective of this work is to detect the prevalence and pattern of clinical manifestations, organ damage and outcome in adult Egyptian patients with juvenile and adult onset SLE and comparing males to females, taking into consideration the risk factors associated with damage.
Patients and methods
The study, descriptive and cross-sectional, included 239 Egyptian SLE patients fulfilling the updated ACR revised criteria for the classification of SLE [15] . The patients were attending the Rheumatology Clinic in New Children Hospital and the Rheumatology and Internal medicine out-patient Clinics of Cairo University Hospitals as well as the Pediatric outpatient of the National research centre, Cairo during 2010.
The patients were grouped according to the age at disease onset, group 1 including the adult onset SLE (a-SLE) and group 2 the juvenile-onset SLE (J-SLE) patients with the disease starting before the age of 16 years. All the patients had the disease duration P6 months at study entry. Full history taking, thorough clinical examination, laboratory and relevant radiological investigations were performed for all the patients. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [16] while assessment of organ damage was made using the Systemic Lupus International Collaborating Clinics/ACR (SLICC/ACR) index [17] and the pediatric version was used for the juvenile-onset SLE patients [18] . The clinical manifestations are described based on the SLEDAI and SLICC items.
Renal biopsies were done only in patients with renal involvement and compromise, the specimens processed for light microscopy and classified according to the 1982 modified WHO morphologic classification of lupus nephritis [19] . The renal class was retrospectively considered in 116 patients who had a biopsy performed during the year preceding the study. The revised version of classification criteria for Sjo¨gren's syndrome (SS) was considered for its diagnosis [20] . Fibromyalgia syndrome was considered according to the ACR criteria [21] . The study has been approved by local ethics committee and it conforms to the standards currently applied in Cairo University Teaching Hospitals.
Statistics. For statistical analysis the total group of patients was divided in two subgroups according to the age at symptoms onset: Group I: adult onset SLE (a-SLE) (>16 years) and Group II: juvenile onset Lupus (j-SLE) (616 years). They were also analyzed according to gender (male-SLE vs. female-SLE). Analysis of data was performed with a statistical package for the social sciences (SPSS) version 15. Data were presented as mean ± standard deviation and percentage. Mann-Whitney test was used for analysis of two non-parametric quantitative data. Correlation was performed by Spearman correlation coefficient. p value was considered significant if <0.05.
Results

Outcome of SLE patients according to the age at disease onset
The study included 239 SLE patients. The a-SLE comprised of 185 patients and 54 J-SLE with the female/male ratio 9.39:1. The ratio was less in J-SLE (6.71:1), being 10.56:1 in adult onset patients. The demographic features, disease activity and damage scores and clinical manifestations of the a-SLE and J-SLE patients are shown in Tables 1-3, respectively. Growth failure in 18 patients (33.33%) and delayed puberty in 8 patients (14.81%) were further considered in the 54 J-SLE patients' damage.
The laboratory results of the studied SLE patients included ESR 1st hour 53.39 ± 29.75 mmHg, hemoglobin level 10.86 ± 2.19 g%, WBC count 7.5 ± 4.1 · 10 3 mm À3 , platelet count 310 ± 124.61 · 10 3 mm À3 , AST 31.91 ± 23.24 U/l, ALT 28.41 ± 22.71 U/l, albumin 3.62 ± 0.66 g/dl, creatinine 0.76 ± 0.4 mg/dl, urea 35.76 ± 21.64 mg/dl and serum uric acid 5.57 ± 2.45 mg/dl. There was no significant difference in these laboratory results according to the age at disease onset. However, the urine protein level in g/24 h (0.78 ± 1.12) was significantly higher in adult SLE patients (0.88 ± 1.23 g/ 24 h) compared to juvenile onset (0.47 ± 0.5 g/24 h). The complement factor C3 was 0.69 ± 0.35 mg/dl while C4 was 0.24 ± 0.41 mg/dl. The anticardiolipin (ACL) IgG was 16.06 ± 9.81 IU/l and the ACL IgM 13.51 ± 6.85 IU/l, anti-Ro 17 ± 14.06 U/ml and anti-La 12.38 ± 8.94 U/ml. The antinuclear antibody (ANA) was positive in 223 patients (93.31%) while the anti-double stranded DNA was positive in 158 patients (66.11%). Again there was no difference of significance in these laboratory results according to the age of disease onset.
All patients with renal involvement (62.76%) underwent renal biopsy and according to the WHO classification of lupus nephritis the patients were classified as shown in Table 4 . Eleven patients had acute renal failure and another 10 The prevalence of damage was 75.14% in a-SLE and 85.19% in J-SLE patients with the majority having a low damage index. The prevalence was higher in males (91.3%) compared to females (75.93%). Hemolytic anemia was present in 26.78%, thrombocytopenia in 46 patients (19.25%) and leucopenia in 54 (22.59%) mostly a-SLE. Heavy proteinuria P3.5 g/24 h was present in 3 a-SLE patients. The lipid profile was mildly altered and insignificantly different according to age at disease onset or gender.
The SLICC significantly negatively correlated with the age at disease onset (r = À0.2, p = 0.002) and significantly correlated with the SLEDAI (p < 0.0001) and disease duration (r = 0.23, p < 0.0001). The SLEDAI significantly correlated with the creatinine, urea, 24 h urine protein and steroid dose (r = 0.15, p = 0.04; r = 0.27, p = 0.001; r = 0.25, p < 0.0001 and r = 0.3, p < 0.0001, respectively). While it negatively correlated with albumin level (r = À0.49, p = 0.0001). The steroid dose significantly correlated with proteinuria (r = 0.28, p < 0.0001) and negatively with C3 (r = À0.22, p = 0.013). Anti-Ro and anti-La significantly correlated with the SLEDAI and SLICC (p < 0.0001). Furthermore, the anti-cardiolipin IgG and IgM significantly correlated with the SLEDAI (r = 0.4, p = 0.007 and r = 0.51, p = 0.001). The renal biopsy classes were comparable in the a-SLE and J-SLE patients. Renal biopsy class significantly correlated with creatinine, 24 h urinary protein and uric acid (r = 0.32, p < 0.0001; r = 0.2, p = 0.005 and r = 0.38, p = 0.009, respectively) and negatively correlated with C3 (r = À0.22, p = 0.01).
The mean steroid dose used by all the patients was 19.83 ± 11.8 mg/day being slightly higher in a-SLE patients. The different treatment regimens used for the patients at the time of the study are shown in Table 5 . Plasmapheresis was performed in three patients as an additional therapy, 2 tried IVIg therapy and oral anticoagulants was used by 45. Cyclophosphamide was given to 42 (77.77%) J-SLE and 85 (45.95%) a-SLE patients. Fig. 1 shows the mean SLICC/ACR damage index in the studied SLE patients. The biopsy classes tended to be higher in male SLE patients. The mean steroid dose was significantly higher in the females (20.31 ± 11.99 mg/day) compared to the males (15.45 ± 8.99 mg/day) (r = 0.07, p = 0.027). Hypertension was present in 60 females (27.77%) and 4 males (17.39%) with no gender differences.
Outcome of SLE patients according to the gender
Six of the patients (2.51%) who were included in the study died later on during the following year, four were J-SLE and the other two were a-SLE. They all had lupus nephritis and were on hemodialysis, two had uncontrolled hypertension with heart failure and another died from pulmonary edema; they were four females and two males. Mortality was due to the underlying renal disease and the superimposed complications.
Discussion
In the present study, the SLICC was significantly higher in the J-SLE patients being higher in males with the majority of all SLE patients having a low damage index. In harmony with the present results are the findings that disease onset is more severe in childhood-onset patients [22, 23] with a higher and earlier risk of damage being more in males [24] . In a-SLE studies, damage was present in 44.8% [25] and 31% of patients [26] . The rate of damage in this study was higher than that observed in comparable studies which could be acknowledged to the many races included, while the current study included only Egyptians, and the differences in number of studied patients. Moreover, the mortality rate was higher in those studies compared to that of the present study which may explain the increased morbidity and rate of damage in the patients included in this study. The increased damage in J-SLE was attributed to renal and musculoskeletal involvement [27] . The SLICC significantly negatively correlated with the age at disease onset in the present study, which could explain the poorer outcome, more severe disease expression and more aggressive therapy observed in younger children which is similar to the findings of Al-Mayouf and Al-Sonbul [24] . In a-SLE patients, gender influences the clinical expression of disease independent of age, while both gender and age do not affect the overall damage score [28] . After years of follow up, 88% of J-SLE patients continued to have a high SLEDAI with 42% of them having a mean SLICC of 1.62 ± 2.1 [7] . The SLEDAI and SLICC significantly correlated in this study. However, it was concluded that both remain independent SLE outcome measures [29] . The female to male ratio was 9.39:1 being 6.86:1 in J-SLE compared to 10.56:1 in a-SLE. In other studies on J-SLE patients it was 4.6:1 [30] , 5.85:1 [24] and 4.7:1 [31] which may be attributable to ethnic differences. Furthermore, the ratio in a-SLE was higher which ensures the importance of hormonal factors in the clinical expression of the disease. The mean disease duration was 7.87 ± 5.52 years. The prevalence of damage was higher in J-SLE (83.64%) compared to a-SLE patients (75.14%) and in male SLE patients compared to females. In other studies, organ damage was observed in 50-60% of patients [9, 32] , in a Brazilian study it was 32% [33] and in another study 61% [34] . Conversely, there was no significant gender difference in the major organ manifestation in a-SLE patients [26] . Although the renal manifestations were more in J-SLE, the 24 h proteinuria was significantly higher in a-SLE which suggests that renal involvement is not the only factor responsible for the higher damage index and mortality seen in J-SLE. Active disease especially renal at presentation and over time [22] and damage at follow-up were more in J-SLE [31] . The most frequent systems involved were the mucocutaneous, renal, musculoskeletal and neuropsychiatric [32, 35] .
Variations in SLE clinical manifestations and outcomes are related to gender differences. In this study, serositis, renal involvement and SLICC were higher in males. Similarly, in a study on adult SLE patients, males were more likely to have serositis, renal involvement with end-stage renal disease and a poorer outcome as the SLICC was 2.7 ± 2.7 vs 1.0 ± 1.6 in females [12] . Young SLE women had more Raynauds, photosensitivity and mucosal ulcers. However, there were no significant differences regarding the clinical and laboratory features, disease activity or damage index scores between the two genders [28, 30] .
In J-SLE patients, arthritis occurred in 63.63%, mucocutaneous manifestations in 65.45%, renal involvement in 70.6% and CNS disease in 38.18%. In similar studies on J-SLE, the most common clinical manifestations were arthritis (67%), malar rash (66%), nephritis (55%), and CNS disease (27%) [31] . Renal disease and SLEDAI were higher in J-SLE [22] contributing to the higher mortality rate [36] . In the present study, acute renal failure was present in 11 patients and another 10 passed into ESRD. In another study, lupus nephritis in J-SLE was present in 51% and acute renal failure in 20.08% [37] . Similar to our findings, in J-SLE patients the hematological manifestations and anti-DNA antibodies were more frequent [38] . Pulmonary involvement was seen in 27.92% of cases being higher in J-SLE. Conversely, it was low and with no radiographic evidence of ILD in J-SLE given the higher frequency in a-SLE [39] . Growth failure was present in 32.73% and delayed puberty in 14.55% of J-SLE as 76.36% were receiving cyclophosphamide and ovarian reserve was significantly reduced [7] . Renal damage and growth failure were observed most frequently in J-SLE [40] . Lupus nephritis has been described as the most serious complication of SLE and the strongest predictor of poor outcome. While the incidence of childhood SLE is relatively low, renal involvement appears to be more common and severe [41] .
Fibromyalgia syndrome was present in 29.58% being higher in J-SLE patients. The prevalence of FMS in SLE is consistently 20-25% [42] and this association may pose a diagnostic dilemma [43] . The SS in the present study was present in a higher number of a-SLE females. Anti-Ro and anti-La significantly correlated with the SLEDAI and SLICC during the study. In accordance was the presence of SS in 14% of SLE patients especially older females [44] . Secondary SS is as high as 90% and a new subset has been suggested in late-onset patients with anti-SSA/Ro antibodies [45, 46] .
In the present study, the kidney was the commonly involved and an important cause of death. The mortality rate was higher in J-SLE patients and also in males. Early damage is associated with a higher mortality rate [47] . Renal disease and mortality were significantly higher in SLE men [12, 48] .
In conclusion, measuring organ damage in SLE is important with special concern for juvenile-onset and male patients thus allowing for designing new treatments aimed at improving the control of disease activity and minimizing the development of irreversible damage. There is a high rate of disease activity Figure 1 The mean SLICC/ACR damage index in the adult and juvenile onset SLE patients and their gender differences. and damage in Egyptian SLE patients being more common in J-SLE. The kidney appeared to be commonly involved, especially in males, indicating the importance of regular screening for early and appropriate management.
